Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:420134.
doi: 10.1155/2014/420134. Epub 2014 Feb 10.

Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities

Affiliations
Review

Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities

Pierre-Régis Burgel et al. Biomed Res Int. 2014.

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, the severity of which is assessed using forced expiratory volume in 1 sec (FEV1, % predicted). Cohort studies have confirmed that COPD patients with similar levels of airflow limitation showed marked heterogeneity in clinical manifestations and outcomes. Chronic coexisting diseases, also called comorbidities, are highly prevalent in COPD patients and likely contribute to this heterogeneity. In recent years, investigators have used innovative statistical methods (e.g., cluster analyses) to examine the hypothesis that subgroups of COPD patients sharing clinically relevant characteristics (phenotypes) can be identified. The objectives of the present paper are to review recent studies that have used cluster analyses for defining phenotypes in observational cohorts of COPD patients. Strengths and weaknesses of these statistical approaches are briefly described. Description of the phenotypes that were reasonably reproducible across studies and received prospective validation in at least one study is provided, with a special focus on differences in age and comorbidities (including cardiovascular diseases). Finally, gaps in current knowledge are described, leading to proposals for future studies.

PubMed Disclaimer

References

    1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. European Respiratory Journal. 2006;28(3):523–532. - PubMed
    1. Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research. 2010;11, article 122 - PMC - PubMed
    1. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. American Journal of Respiratory and Critical Care Medicine. 2010;182(5):598–604. - PMC - PubMed
    1. Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. Journal of General Internal Medicine. 2007;22(4):464–469. - PMC - PubMed
    1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. European Respiratory Journal. 2009;33(5):1165–1185. - PubMed

MeSH terms